FDA Accelerates Psychedelic Therapy Development
The FDA accelerated regulatory action on psychedelic therapies on April 24, 2026, following Trump's April 18 executive order directing faster access to treatments for serious mental illness.
Objective Facts
The FDA announced on April 24, 2026, that it is accelerating regulatory action on a new class of psychedelic-based therapies following President Trump's April 18 executive order directing the Department of Health and Human Services to speed up access to treatments for serious mental illness. The FDA granted priority review vouchers to three companies: Compass Pathways for its synthetic psilocybin formulation COMP360 targeting treatment-resistant depression, the Usona Institute for psilocybin addressing major depressive disorder, and Transcend Therapeutics for methylone therapy aimed at PTSD. The agency also cleared an early phase clinical study of noribogaine hydrochloride as a potential treatment for alcohol use disorder, marking the first instance of an FDA-approved U.S. clinical study of this ibogaine-derived compound. Trump's executive order includes a $50 million investment in state governments to study how psychedelics might benefit people struggling with mental health disorders. Democratic members of Congress have raised concerns that vouchers have gone to companies that are politically favored by the White House, including those that have agreed to cut prices on their medications.
Left-Leaning Perspective
Democratic members of Congress have raised concerns that the FDA's priority review vouchers for psychedelic drugs have gone to companies that are politically favored by the White House, particularly those that have agreed to cut prices on their medications. Psychedelic law experts, including Mason Marks of Harvard Law School's Petrie-Flom Center, expressed concern that with pressure from the White House, treatments might be rushed through approval that should not be, warning that "it could really set back what progress has been made." Medical experts like psychiatrist Richard Friedman of Weill Cornell Medicine urged caution about expedited FDA approval of experimental therapies, emphasizing that the critical issue is ensuring "we're giving short shrift to the rigorous analysis of safety." Critics have pointed out that at the Department of Health and Human Services under Secretary Robert F. Kennedy Jr., the growing interest in psychedelics coexists with broader skepticism toward vaccines and antidepressants, with some advocates in the Make America Healthy Again movement seeking to dismantle aspects of the FDA approval process rather than review drugs through traditional means, reflecting a coalition defined by broad skepticism toward credentialed institutions. Left-leaning coverage has largely focused on safety concerns and the potential for political favoritism to influence FDA decision-making through the voucher program. The coverage emphasizes scientific rigor over speed and questions whether the executive order prioritizes expedience over patient safety.
Right-Leaning Perspective
Melissa Lavasani, founder of the Psychedelic Medicine Coalition, stated that the Trump administration has demonstrated much more openness in dialogue with the federal government compared to the Biden administration's "extra layer of political cautiousness." Reason Magazine editorial commentary praised Trump's order as "both good policy and an encouraging sign of prospects for the movement for psychedelic freedom," expressing hope for "a similar cascade of support for legalization, similar to dam-breaking that's happened with marijuana legalization in the states." Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, argued that Trump's White House is not bound by the same political worries as Biden's was, and noted that sometimes "it's easier for this particular Republican administration to be more bold" on issues like psychedelic research, similar to how Nixon could open relations with China. Jay Kopelman, former Marine Corps lieutenant colonel and CEO of Mission to Live Foundation, told Fox News that the president's action "opens a pathway to research that will further open doors to expedited approval of this life-saving medicine as a treatment for our veterans — and society — who have suffered for decades from treatment-resistant PTSD, TBI (traumatic brain injury) and depression." The Multidisciplinary Association for Psychedelic Studies noted that the Trump order would "give pretty substantial cover for Republican governors and legislatures to step into the ring in terms of funding research programs at their universities," given the significant stigma around Schedule I drugs. Right-leaning coverage has emphasized the Trump administration's bold departure from decades of drug war orthodoxy and praised the potential to help veterans and patients with treatment-resistant conditions through faster approval pathways.
Deep Dive
The Trump administration's executive order represents a significant shift in federal policy from obstruction toward accommodation regarding psychedelics, with the difference between the 2024 FDA rejection of MDMA and the 2026 psychedelic acceleration potentially reflecting changing political priorities, growing public acceptance of these treatments, or the accumulation of sufficient safety data to satisfy regulatory concerns. When Joe Biden was president, federal agencies studied the medical potential of psychedelics, but his administration's FDA rejected Lykos Therapeutics' application to offer ecstasy alongside talk therapy as a treatment for PTSD. Biden also began the process of marijuana rescheduling, but it was not completed before his term ended. Trump's announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support. The core debate centers on whether expedited review serves desperate patients with treatment-resistant conditions or whether it compromises scientific rigor. The American Psychiatric Association welcomes federal investment while emphasizing that current scientific evidence is not sufficient to support use of these therapies outside of approved research settings, stating that rigorous study, strong patient protections, and physician-led oversight will be essential to ensure safety and effectiveness. Both perspectives acknowledge that psychedelics show therapeutic promise, but disagree on whether the 1-2 month review timeline appropriately balances urgency with safety. Since 2021, Texas and about 30 states have passed or proposed bipartisan legislation to fund psychedelic research, propose regulatory reform, create regulated access programs, and establish task forces to plan how these treatments will be implemented in the U.S. healthcare system, with Logan Davidson, legislative director of Veterans Exploring Treatment Solutions, stating that "nothing we're seeing play out on the national stage would have happened without Texas." The unresolved question is whether the FDA can maintain its approval standards while meeting the administration's aggressive timeline goals, and whether insufficient funding for therapist training and clinical infrastructure will create bottlenecks even if drugs are approved.